Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril or Indapamide SR in the Treatment of Hypertensive Patients whose Blood Pressure is Not Controlled by Monotherapy

Trial Profile

A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril or Indapamide SR in the Treatment of Hypertensive Patients whose Blood Pressure is Not Controlled by Monotherapy

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indapamide (Primary) ; Ramipril (Primary) ; Captopril
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Egis Pharmaceuticals

Most Recent Events

  • 12 Sep 2024 This trial has been completed in Hungary, according to European Clinical Trials Database record.
  • 26 Nov 2021 Planned number of patients changed from 226 to 221.
  • 19 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top